Shih JY - Search Results

1

IL-8 confers resistance to EGFR inhibitors by inducing stem cell properties in lung cancer.

Liu YN, Chang TH, Tsai MF, Wu SG, Tsai TH, Chen HY, Yu SL, Yang JC, Shih JY. Liu YN, et al. Among authors: shih jy. Oncotarget. 2015 Apr 30;6(12):10415-31. doi: 10.18632/oncotarget.3389. Oncotarget. 2015. PMID: 25871388 Free PMC article.

2

Tumor-associated antigen L6 and the invasion of human lung cancer cells.

Kao YR, Shih JY, Wen WC, Ko YP, Chen BM, Chan YL, Chu YW, Yang PC, Wu CW, Roffler SR. Kao YR, et al. Among authors: shih jy. Clin Cancer Res. 2003 Jul;9(7):2807-16. Clin Cancer Res. 2003. PMID: 12855661

3

Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer.

Shih JY, Gow CH, Yu CJ, Yang CH, Chang YL, Tsai MF, Hsu YC, Chen KY, Su WP, Yang PC. Shih JY, et al. Int J Cancer. 2006 Feb 15;118(4):963-9. doi: 10.1002/ijc.21458. Int J Cancer. 2006. PMID: 16152581

4

Gefitinib treatment for non-small cell lung cancer -- a study including patients with poor performance status.

Su WP, Yang CH, Yu CJ, Shih JY, Hsu C, Yang PC. Su WP, et al. Among authors: shih jy. J Formos Med Assoc. 2005 Aug;104(8):557-62. J Formos Med Assoc. 2005. PMID: 16193176

5

Transcription repressor slug promotes carcinoma invasion and predicts outcome of patients with lung adenocarcinoma.

Shih JY, Tsai MF, Chang TH, Chang YL, Yuan A, Yu CJ, Lin SB, Liou GY, Lee ML, Chen JJ, Hong TM, Yang SC, Su JL, Lee YC, Yang PC. Shih JY, et al. Clin Cancer Res. 2005 Nov 15;11(22):8070-8. doi: 10.1158/1078-0432.CCR-05-0687. Clin Cancer Res. 2005. PMID: 16299238

6

Radiotherapy in lung adenocarcinoma with brain metastases: effects of activating epidermal growth factor receptor mutations on clinical response.

Gow CH, Chien CR, Chang YL, Chiu YH, Kuo SH, Shih JY, Chang YC, Yu CJ, Yang CH, Yang PC. Gow CH, et al. Among authors: shih jy. Clin Cancer Res. 2008 Jan 1;14(1):162-8. doi: 10.1158/1078-0432.CCR-07-1468. Clin Cancer Res. 2008. PMID: 18172267

7

Lung adenocarcinoma with good response to erlotinib after gefitinib treatment failure and acquired T790M mutation.

Wu SG, Shih JY, Yu CJ, Yang PC. Wu SG, et al. Among authors: shih jy. J Thorac Oncol. 2008 Apr;3(4):451-2. doi: 10.1097/JTO.0b013e318169e32a. J Thorac Oncol. 2008. PMID: 18379370 Free article. No abstract available.

8

Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy.

Yang CH, Yu CJ, Shih JY, Chang YC, Hu FC, Tsai MC, Chen KY, Lin ZZ, Huang CJ, Shun CT, Huang CL, Bean J, Cheng AL, Pao W, Yang PC. Yang CH, et al. Among authors: shih jy. J Clin Oncol. 2008 Jun 1;26(16):2745-53. doi: 10.1200/JCO.2007.15.6695. J Clin Oncol. 2008. PMID: 18509184 Clinical Trial.

9

First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer.

Wu JY, Yu CJ, Yang CH, Wu SG, Chiu YH, Gow CH, Chang YC, Hsu YC, Wei PF, Shih JY, Yang PC. Wu JY, et al. Among authors: shih jy. Am J Respir Crit Care Med. 2008 Oct 15;178(8):847-53. doi: 10.1164/rccm.200803-389OC. Epub 2008 Jun 26. Am J Respir Crit Care Med. 2008. PMID: 18583573

10

Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response.

Wu JY, Wu SG, Yang CH, Gow CH, Chang YL, Yu CJ, Shih JY, Yang PC. Wu JY, et al. Among authors: shih jy. Clin Cancer Res. 2008 Aug 1;14(15):4877-82. doi: 10.1158/1078-0432.CCR-07-5123. Clin Cancer Res. 2008. PMID: 18676761

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

353 results

Search Page

Filters